TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Sell" at StockNews.com

StockNews.com lowered shares of TG Therapeutics (NASDAQ:TGTX - Free Report) from a hold rating to a sell rating in a research report sent to investors on Friday morning.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. increased their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a report on Monday, November 25th. HC Wainwright reissued a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. TD Cowen started coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $50.00 price objective on the stock. Finally, The Goldman Sachs Group upped their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock traded up $1.43 on Friday, hitting $32.91. 1,621,529 shares of the company's stock were exchanged, compared to its average volume of 2,572,178. TG Therapeutics has a 1 year low of $12.84 and a 1 year high of $36.84. The company has a 50-day simple moving average of $31.57 and a 200-day simple moving average of $26.66. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a market capitalization of $5.12 billion, a PE ratio of -329.07 and a beta of 2.26.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analysts' expectations of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics's revenue for the quarter was down 49.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 earnings per share. As a group, equities analysts anticipate that TG Therapeutics will post 0.08 EPS for the current year.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now directly owns 100,195 shares of the company's stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,358 shares of company stock worth $781,497. 10.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp grew its holdings in TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock valued at $212,712,000 after purchasing an additional 2,398,015 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after buying an additional 725,371 shares during the last quarter. Braun Stacey Associates Inc. purchased a new stake in shares of TG Therapeutics in the fourth quarter worth approximately $13,328,000. Castellan Group bought a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $8,539,000. Finally, Public Sector Pension Investment Board purchased a new position in TG Therapeutics during the 3rd quarter valued at $6,619,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.